ERBB2 and breast carcinoma: For instance, the OlympiA trial showed that administering olaparib postoperatively for 1 year to patients with HER2-negative breast cancer and BRCA pathogenic variant improved the invasive-disease-free survival (IDFS) and overall survival (OS) (14), (18).